- Home
- LPCN vs BIVI Comparison
LPCN vs BIVI Comparison
Compare LPCN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- BIVI
- Stock Information
- Founded
- LPCN 1997
- BIVI 2013
- Country
- LPCN United States
- BIVI United States
- Employees
- LPCN N/A
- BIVI N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- BIVI Health Care
- Exchange
- LPCN Nasdaq
- BIVI Nasdaq
- Market Cap
- LPCN 16.1M
- BIVI 18.6M
- IPO Year
- LPCN N/A
- BIVI N/A
- Fundamental
- Price
- LPCN $3.17
- BIVI $1.08
- Analyst Decision
- LPCN Strong Buy
- BIVI Strong Buy
- Analyst Count
- LPCN 2
- BIVI 1
- Target Price
- LPCN $9.00
- BIVI $30.00
- AVG Volume (30 Days)
- LPCN 71.7K
- BIVI 282.1K
- Earning Date
- LPCN 05-08-2025
- BIVI 05-12-2025
- Dividend Yield
- LPCN N/A
- BIVI N/A
- EPS Growth
- LPCN N/A
- BIVI N/A
- EPS
- LPCN N/A
- BIVI N/A
- Revenue
- LPCN $3,674,834.00
- BIVI N/A
- Revenue This Year
- LPCN N/A
- BIVI N/A
- Revenue Next Year
- LPCN N/A
- BIVI N/A
- P/E Ratio
- LPCN N/A
- BIVI N/A
- Revenue Growth
- LPCN N/A
- BIVI N/A
- 52 Week Low
- LPCN $2.68
- BIVI $0.62
- 52 Week High
- LPCN $11.79
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- LPCN 43.78
- BIVI 53.42
- Support Level
- LPCN $3.00
- BIVI $1.07
- Resistance Level
- LPCN $3.49
- BIVI $1.13
- Average True Range (ATR)
- LPCN 0.34
- BIVI 0.06
- MACD
- LPCN -0.05
- BIVI 0.00
- Stochastic Oscillator
- LPCN 16.50
- BIVI 65.99
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.